L
Lysosomal Therapeutics
Delivering cures for neurodegenerative diseases
About Lysosomal Therapeutics
Lysosomal Therapeutics Inc. (LTI) was a biopharmaceutical company established in 2011, headquartered in Cambridge, Massachusetts. The company focused on developing small-molecule therapies for severe neurodegenerative diseases, particularly those with a genetic link to lysosomal dysfunction. In October 2020, LTI was acquired by BIAL, a Portuguese pharmaceutical company, which then established BIAL Biotech in the United States to continue the development of LTI's programs.
LTI’s scientific foundation was built upon the research of its founders, which includes Dr. Dimitri Krainc, Dr. Peter Lansbury, Henri Termeer, and Bob Carpenter. Dr. Krainc's work at Massachusetts General Hospital and Harvard Medical School was instrumental in launching the company. His research focused on defining the molecular pathways in neurodegeneration, especially by uncovering pathogenic mechanisms related to mitochondria and lysosomes. Dr. Lansbury, a Professor of Neurology at Harvard Medical School and Chief Scientific Officer at LTI, has a deep background in the biochemistry of protein aggregation in diseases like Alzheimer's and Parkinson's. He previously founded Link Medicine, which was sold to AstraZeneca. The company's founding President and CEO was Kees Been, a biotech industry veteran with experience at companies like Biogen and a background in molecular biology and business administration.
The company's primary business was the research and development of drug candidates to treat the root cause of neurodegenerative disorders like Parkinson's disease. LTI's approach was centered on the clinically validated connection between lysosomal storage disorders, such as Gaucher disease, and a predisposition to Parkinson's. Specifically, the company worked on developing molecules that could activate the glucocerebrosidase (GCase) enzyme. Mutations in the GBA1 gene lead to reduced GCase activity, which is a significant risk factor for Parkinson's disease, contributing to the toxic aggregation of the alpha-synuclein protein. LTI developed small molecules capable of crossing the blood-brain barrier to increase GCase activity, aiming to restore lysosomal function and normalize alpha-synuclein levels. Its lead drug candidate, LTI-291, was designed to stimulate GCase activity in the brain and was tested in human clinical trials for safety and tolerability in both healthy volunteers and individuals with Parkinson's carrying a GBA1 mutation.
LTI's business model relied on venture capital funding and strategic partnerships with larger pharmaceutical companies. The company successfully raised significant capital through multiple funding rounds, including a $4.8 million seed round in 2014 and a $20 million Series A round in 2015. Investors included prominent venture funds such as Atlas Venture, Hatteras Venture Partners, and the corporate venture arms of Roche, Eli Lilly, and Sanofi. The company also received grant funding from The Michael J. Fox Foundation for Parkinson's Research to support a biomarker initiative aimed at patient selection for clinical trials. In 2017, Allergan purchased an exclusive option to acquire LTI, though the deal did not proceed, leading to the eventual acquisition by BIAL in 2020.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 25.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 3 companies, latest Aug 2016
- Capital deployed
- $35M
- Preferred round
- SERIES A
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2017 | $0 | — | Allergan | — |
| SERIES A✓Equity / VC | Feb 2015 | $20M | $80M | Atlas Venture | — |
Growth signals
Latest recorded traffic for Lysosomal Therapeutics is 140 monthly website visits, down 70.8% over the last three months. Lysosomal Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Amylyx PharmaceuticalCambridge, United StatesDeveloping new treatments for ALS, Alzheimer's, and all neurodegenerative diseases
$3.5Bvaluation
Artax BiopharmaCambridge, United StatesBiopharmaceutical company that develops new therapies for autoimmune and inflammatory diseases
$104Mvaluation
NanoString TechnologiesSeattle, United StatesProvider of life science tools for translational research based on the nCounter® technology for single-molecule counting.
$154Mvaluation
Lysosomal Therapeutics in the Cambridge ecosystem
The Lysosomal Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Other known investors3 additional known investors
Allergan
Baylor College of Medicine
Sanofi Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lysosomal Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lysosomal Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










